CVS Health to Terminate SilverScript Choice PDP in 13 Regions for 2027
CVS Health is terminating its SilverScript Choice stand-alone prescription drug plan in 13 regions for the 2027 coverage year, impacting approximately 950,000 enrollees.
Stocks · News reference
CVS Health Reports Worsening Shortages of Estradiol Injections
CVS Health stated that manufacturers have struggled to supply certain strengths of estradiol injections, with the situation deteriorating in recent weeks.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
US Department of Labor to Require PBM Transparency Disclosures
The U.S. Department of Labor is expected to introduce new regulations requiring Pharmacy Benefit Managers (PBMs) to disclose detailed information regarding their fees and revenue sources to employer clients.
CVS Health Engages in Medicare Negotiations to Expand Pharmacist Roles and GLP-1 Access
CVS Health is in discussions with Medicare to broaden the scope of pharmacist-led chronic disease management and improve patient access to high-cost GLP-1 medications.